# NB2013-HR German (GPOH) / Dutch (DCOG) Trial

> **NCT02641782** · PHASE2 · TERMINATED · sponsor: **University of Cologne** · enrollment: 3 (actual)

## Conditions studied

- Neuroblastoma

## Interventions

- **DRUG:** antibody ch14.18
- **DRUG:** GM-CSF
- **DRUG:** IL-2 i.v.
- **DRUG:** IL-2 s.c.
- **DRUG:** Retinoic acid

## Key facts

- **NCT ID:** NCT02641782
- **Lead sponsor:** University of Cologne
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2015-11
- **Primary completion:** 2016-12-23
- **Final completion:** 2017-01-30
- **Target enrollment:** 3 (ACTUAL)
- **Why stopped:** Antibody supply was discontinued by United Therapeutics Corporation.
- **Last updated:** 2022-11-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02641782

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02641782, "NB2013-HR German (GPOH) / Dutch (DCOG) Trial". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT02641782. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*